

DAFTAR PUSTAKA

1. WHO. 2016. Report of the 2nd Meeting of the Global AMR Surveillance System (GLASS) Collaborative Platform. 1: 1-48.
2. Nur Y. 2014. Epidemiology and risk factors for invasive candidiasis. 10: 95-105.
3. Wahyuningsih R, Sahbandar IN, et al. 2018. *Candida nivariensis* Isolated from an Indonesian Human Immunodeficiency Virus-Infected Patient Suffering from Oropharyngeal Kandidiasis. 46: 388–91.
4. Mayer FL, Wilson D, et al. 2013. *Candida albicans* pathogenicity mechanisms. 4: 119-28.
5. Gow NAR, Yadav B. 2017. Microbe Profile: *Candida albicans*: a shape-changing, opportunistic pathogenic fungus of humans. 163: 1145–7.
6. Oliveira LF De, Olavo A, et al. 2006. In vitro minocycline activity on superinfecting microorganisms isolated from chronic periodontitis patients. 20: 202-6.
7. Cruz MCS, Santos PO, Jr AMB. 2007. Antifungal activity of Brazilian medicinal plants involved in popular treatment of mycoses. 111: 409–12.
8. Holetz FB, Pessini GL. et al. 2002. Screening of Some Plants Used in the Brazilian Folk Medicine for the Treatment of Infectious Diseases. 97: 1027–31.
9. Yustika E. 2015. Pemanfaatan Daun Kersen (*Muntingia calabura* L) dan Daun Sirsak dalam Pembuatan Teh dengan Penambahan Pemanis Daun Stevia. 1: 1-14
10. Haki M. 2009. Efek Ekstrak Daun Talok (*Muntingia calabura* L.) Terhadap Aktivitas Enzim SGPT Pada Mencit yang Diinduksi Karbon Tetraklorida. 1: 1–40.
11. Togami J, Tamura M, et al. 2006. Molecular characterization of the flavonoid biosynthesis of *Verbena hybrida* and the functional analysis of *verbena* and *Clitoria ternatea* F3'5'H genes in transgenic *verbena*. 23: 5–11.
12. Singh R. 2017. Phytochemical Analysis of *Muntingia calabura* Extracts Possessing Anti-Microbial and Anti-Fouling Activities. 9: 826-32.
13. Krishnaveni M, Dhanalakshmi R. 2014. Qualitative and Quantitative Study of Phytochemicals in *Muntingia calabura* L. Leaf and Fruit. 3: 1687–96.
14. Kurniawati A, Mashartini A. 2016. Perbedaan khasiat anti jamur antara ekstrak etanol daun Kersen (*Muntingia calabura* L .) dengan nistatin terhadap pertumbuhan *Candida albicans*. 65: 74–7.
15. Nobile CJ, Schneider HA, et al. 2008. Complementary Adhesin Function in *C. albicans* Biofilm Formation. 18: 1017–24.
16. Berman J, Sudbery PE. 2002. *Candida albicans*: A molecular revolution built on lessons from budding yeast. 3: 918–30.
17. Phan QT, Fratti RA, et al. 2005. N-cadherin mediates endocytosis of *Candida albicans* by endothelial. 280: 10455–61.
18. Phan QT, Myers CL, et al. 2007. Als3 is a *Candida albicans* invasin that binds to cadherins and induces endocytosis by host cells. 5: 10543–57.

19. Naglik JR, Moyes DL, et al. 2011. *Candida albicans* interactions with epithelial cells and mucosal immunity. 13: 963–76.
20. Dalle F, Wächtler B, et al. 2010. Cellular interactions of *Candida albicans* with human oral epithelial cells and enterocytes. 12: 248–71.
21. Robbins N, Uppuluri P, et al. 2011. Hsp90 governs dispersion and drug resistance of fungal biofilms. 9: 1-18.
22. Serpa R, França EJG, et al. 2012. In vitro antifungal activity of the flavonoid baicalein against *Candida* species. 61: 1704–8.
23. Chung KT, Lu Z, et al. 1998. Mechanism of inhibition of tannic acid and related compounds on the growth of intestinal bacteria. 36: 1053–60.
24. Rao A, Zhang Y, et al. 2010. Mechanism of antifungal activity of terpenoid phenols resembles calcium stress and inhibition of the TOR pathway. 54: 5062–9.
25. Moyo B, Julius PM, et al. 2012. Antimicrobial activities of *Moringa oleifera* Lam leaf extracts. 11: 2797–802.
26. Daglia M. 2012. Polyphenols as antimicrobial agents. 23: 174–81.
27. Jawetz. 2007. Jawetz, Melnick & Adelberg's Medical Microbiology: 24th Edition. 48: 857-9
28. Aru W, Sudoyo, et. al. 2014. Buku Ajar Ilmu Penyakit Dalam Jilid III Edisi VI. 4: 755-62
29. Nelwan EJ, Wisaksana R. 2010. Clinical manifestation of oral kandidiasis in a HIV patient. 42: 43–4.
30. Vincent JL, Anaissie E, et al. 1998. Epidemiology, diagnosis and treatment of systemic *Candida* infection in surgical patients under intensive care. 24: 206–16.
31. Refai M, El-Enbaawy M, et al. 2015 Monograph On *Candida albicans*. 1: 1-247.
32. Lingala SM, Ghany MG. 2016. Control of *Candida albicans* morphology and pathogenicity by post-transcriptional mechanisms. 25: 289–313.
33. Molero G, Dfcz-Orejas R, et al. 1998. *Candida albicans*: Genetics, dimorphism and pathogenicity. 1: 95–106.
34. Sastra S. 2004. Efek xylitol dalam berbagai konsentrasi dan durasi terhadap jumlah koloni *candida albicans* (uji In vitro). 1: 4–24.
35. Kaminskyj SGW. 2008. Effective and flexible methods for visualizing and quantifying endorhizal fungi. 9: 337-49.
36. Nobile CJ, Johnson AD. 2015. *Candida albicans* Biofilms and Human Disease.; 69: 71–92.
37. Imron Nasution A. 2013. Virulence Factor and Pathogenicity of *Candida albicans* in Oral Kandidiasis. 4: 267–71.
38. Bayer C, Chase MW, et al. 2008. Muntingiaceae , a New Family of Dicotyledons with Malvacean Affinities. 47: 37–42.
39. Patel PK, Vyas V, et al. 2016. *Muntingia calabura* L. (Elaeocarpaceae): A New Generic Record to the Flora of Gujarat State, India. 5: 1269.
40. Muslimin, L, Hasyim I, et al. 2019. Nutrient Content, Mineral Content and Antioxidant Activity of *Muntingia calabura* Linn. 18: 726–32.

41. Zahara M. 2018. Kajian Morfologi dan Review Fitokimia Tumbuhan Kersen (*Muntingia calabura* L). 5: 69–74.
42. Bimastani N. 2016. Efek Antimikroba Air Perasan Umbi Bawang (*Eleutherine palmifolia* (L.) Merr.) terhadap Pertumbuhan *Staphylococcus aureus*. 1: 9–26.
43. Trevor AJ, Katzung BG, *et al.* 2007. *Katzung & Trevor's Pharmacology: Examination & Board Review*. 12: 849-59.
44. Maertens JA. 2004. History of the development of azole derivatives. 10: 1–10.
45. Sheehan DJ, Hitchcock CA, *et al.* 1999. Current and emerging azole antifungal agents. 12: 40–79.
46. Wood AJ, Como JA, *et al.* 1994. Oral Azole Drugs as Systemic Antifungal Therapy. 330: 263–72.
47. Galgiani JN, Ampel NM, *et al.* 2016. Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of *Coccidioidomycosis*. 63: 112–46.
48. Amichai B, Grunwald MH. 1998. Adverse drug reactions of the new oral antifungal agents - Terbinafine, fluconazole, and itraconazole. 37: 410–15.
49. Alsaad AMS, Kaplan YC, *et al.* 2015. Exposure to fluconazole and risk of congenital malformations in the offspring: A systematic review and meta-analysis. 52: 78–82.
50. Pappas PG, Kauffman CA, *et al.* 1995. Alopecia associated with fluconazole therapy. 123: 354–7.
51. Conda L. Sabouraud Dextrose Agar (European Pharmacopoeia) Cat N° : 1024. 1: 24–5.
52. Varghese N. 2014. Microbiology Laboratory Manual. 2014. 1: 1-76.
53. CLSI. 2012. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard Eleventh Edition. 32: 1-58.
54. Sandle T. 2004. Gram ' s Stain : History and Explanation of the Fundamental Technique of Determinative Bacteriology. 54: 3–4.
55. Mutiawati VK. 2016. Pemeriksaan mikrobiologi pada *Candida albicans*. 16: 57–62.
56. Cartwright RY. 1975. A Simple Technique for Observing Germ Tube Formation in *Candida albicans*. 1: 267–8.
57. Tangkumahat FG, Rorong JA, *et al.* 2017. Pengaruh Pemberian Ekstrak Bunga dan Daun Pepaya (*Carica papaya* L .) Terhadap Kadar Glukosa Darah Tikus Wistar (*Rattus norvegicus* L .) yang Hiperglikemik. 17: 143–52.